REFERENCES
1. Scully C, Miller CS, Aguirre Urizar JM, Alajbeg I, Almeida OP, et al. Oral medicine (stomatology) across the globe: birth, growth, and future. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;121:149-57.e5.
2. Radulescu M. The pharmacologic management of common lesions of the oral cavity. Dent Clin North Am 2016;60:407-20.
3. Sankar V, Hearnden V, Hull K, Juras DV, Greenberg MS, et al. Local drug delivery for oral mucosal diseases: challenges and opportunities. Oral Dis 2011;17 Suppl 1:73-84.
4. Stock S, Rubino K, Woo SB, Margolis A, Thomas I, et al. Utilization of compounded medications in an oral medicine practice. Int J Pharm Compd 2016;20:155-8.
5. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
6. WHO. WHO expert committee on specifications for pharmaceutical preparations: WHO technical report series (Report No. 50). Italy: WHO Press; 2016.
7. Higgins JPT, Sterne JAC, Savović J, Page MJ, Hróbjartsson A, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane Methods. Cochrane Database Syst Rev 2016. pp. 29-31.
8. Higgins JPT, Green S. Cochrane handbook for systematic review of interventions. 2011 March [Cited 2017 July 20]. Available from: http://handbook-5-1.cochrane.org. [Last accessed on 17 Aug 2020].
9. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook. 2013 Oct [Cited 2017 July 20]. Available from: http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. [Last accessed on 17 Aug 2020].
10. Lozada-Nur FI, Silverman S. Topically applied fluocinonide in an adhesive base in the treatment of oral vesiculoerosive diseases. Arch Dermatol 1980;116:889-901.
11. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. Journal of Oral Pathol Med 1992;21:456-8.
12. Voute ABE, Schulten EAJM, Langendijk PNJ, Kostense PJ, van der waal I. Fluocinonide in an adhesive base for treatment of oral lichen planus: a double-blind, placebo-controlled clinical study. Oral Surg Oral Med Oral Pathol 1993;75:181-5.
13. Lozada-Nur FI, Miranda C, Maliksi R. Double-blind clinical trial of 0.05% clobetasol propionate ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 1994;77:598-604.
14. Rodstrom PO, Hakebergl M, Jontelll M, Nordin P. Erosive oral lichen planus treated with clobetasol propionate and triamcinolone acetonide in orabase: a double-blind clinical trial. J Dermatol Treat 1994;5:7-10.
15. Buajeeb W, Kraivaphan P, Pobrurksa C. Efficacy of topical retinoic acid compared with topical fluocinolone acetonide in the treatment of oral lichen planus. Oral Surg Oral Med Oral Pathol 1997;83:21-5.
16. Carbone M, Conrotto D, Carrozzo M, Broccoletti R, Gandolfo S, et al. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide. Oral Dis 1999;5:44-9.
17. Lo Muzio L, Valle AD, Mignogna MD, Pannone G, Bucci P, et al. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. J Oral Pathol Med 2001;30:611-7.
18. Campisi G, Giandalia G, De Caro V, Di Liberto C, Arico P, et al. A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic /erosive oral lichen planus. A phase IV, randomized, observer-blinded, parallel group clinical trial. Br J Dermatol 2004;150:984-90.
19. Conrotto D, Carbone M, Carrozzo M, Arduino P, Broccoletti R, et al. Cyclosporine vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial. Br J Dermatol 2006;154:139-45.
20. Scardina GA, Messina P, Carini F, Maresi E. A randomized trial assessing the effectiveness of different concentrations of isotretinoin in the management of lichen planus. Int J Oral Maxillofac 2006;35:67-71.
21. Javadzadeh A, Vatanpour H, Delavarian Z, Momajed A, Esmaeily H, et al. Efficacy of clobetasol, ketoconazole and amitriptyline mouthwash on oral lichen planus. IJPR 2008;7:171-8.
22. Carbone M, Arduino PG, Carrozzo M, Caiazzo G, Broccoletti R, et al. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. J Oral Pathol Med 2009;38:227-33.
23. Cilurzo F, Gennari CGM, Selmin F, Epstein JB, Gaeta GM, et al. A new mucoadhesive dosage form for the management of oral lichen planus: Formulation study and clinical study. Eur J Pharm and Biopharm 2010;76:437-42.
24. Dalirsani Z, Zenouz AT, Mehdipour M, Alavi F, Javadzadeh Y. Comparison of the effect of combination of triamcinolone acetonide and vitamin a mouthwash with triamcinolone mouthwash alone on oral lichen planus. JODDD 2010;4:21-4.
25. Wu Y, Zhou G, Zeng H, Xiong CR, Lin M, et al. A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:188-95.
26. Ahadian H, Akhavan Karbassi MH, Vahidi AR, Owlia F. Comparison of two corticosteroids mouthwashes in treatment of symptomatic oral lichen planus. J Dent Shiraz Univ Med Scien 2012;13:49-53.
27. Arduino PG1, Carbone M, Della Ferrera F, Elia A, Conrotto D, et al. Pimecrolimus vs. tacrolimus for the topical treatment of unresponsive oral erosive lichen planus: a 8 week randomized double-blind controlled study. J Eur Acad Dermatol Venereol 2013;28:475-82.
28. Lee YC, Shin SY, Kim SW, Eun YG. Intralesional injection versus mouth rinse of triamcinolone acetonide in oral lichen planus: a randomized controlled study. Otolaryngol Head Neck Surg 2013;148:443-9.
29. Dillenburg CS, Martins MAT, Munerato MC, Marques MM, Carrard VC, et al. Efficacy of laser phototherapy in comparison to clobetasol for the treatment of oral lichen planus: a randomized controlled trial. Journal of Biomed Optics 2014;19:1-9.
30. Azizi A, Dadrasb OG, Jafaric M, Ghadimd NM, Lawafe S, et al. Efficacy of 0.1% triamcinolone with nanoliposomal carrier formulation in orabase for oral lichen planus patients: A clinical trial. Eur J Integr Med 2015;460:1-6.
31. Jajarm HH, Falaki F, Sanatkhani M, Ahmadzadeh M, Ahrari F, et al. A comparative study of toluidine blue-mediated photodynamic therapy versus topical corticosteroids in the treatment of erosive-atrophic oral lichen planus: a randomized clinical controlled trial. Lasers Med Sci 2015;30:1475-80.
32. Hambly JL, Haywood A, Hattingh L, Nair RG. Comparison between self-formulation and compound-formulation dexamethasone mouth rinse for oral lichen planus: a pilot, randomized, cross-over trial. J Investig Clin Dent 2017;8:1-7.
33. Vaseemuddin S. Comparison of 0.1% dexamethasone and 0.2% triamcinolone acetonide mouthwashes for treatment of oral lichen planus- A clinical study. Int J Com Health Med Res 2017;3:11-4.
34. Vathanasanti A, Kanjanabuch P. Fluocinolone acetonide 0.01% and dexamethasone 0.1% mouthwash in the treatment of symptomatic oral lichen planus. Adv Dent Oral Health 2017;3:555611.
35. Corrocher G, Di Lorenzo G, Mansueto P, Martinelli N, Esposito-Pelitteri M, et al. Comparison of topical tacrolimus 0.1% in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: a 4-week, randomized, double-blind clinical trial. Clin Ther 2006;28:1296-302.
36. Epstein JB, Wong FLW, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. Head Neck 1994;16:539-44.
37. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, et al. Randomized, double blind, placebo-controlled phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004;10:1565-73.
38. Davies AN, Singer J. A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. J Laryngol Otol 1994;108:663-5.
39. Hamlar DD, Schuller DE, Gahbauer RA, Buerki RA, Staubus AE, et al. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 1996;106:972-6.
40. Taweechaisupapong S, Pesee M, Aromdee C, Laopaiboon M, Khunkitti W. Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. Aust Dent J 2006;51:333-7.
41. Khosravani N, Birkhed D, Ekström J. The cholinesterase inhibitor physostigmine for the local treatment of dry mouth: a randomized study. Eur J Oral Sci 2009;117:209-17.
42. Kim JH, Ahn HJ, Choi JH, Jung DW, Kwon JS. Effect of 0.1% pilocarpine mouthwash on xerostomia: double-blind, randomised controlled trial. J Oral Rehabil 2014;41:226-35.
43. Tanigawa T, Yamashita J, Sato T, Shinohara A, Shibata R, et al. Efficacy and safety of pilocarpine mouthwash in elderly patients with xerostomia. Spec Care Dentist 2015;35:164-9.
44. Sholapurkar AA, Pai KM, Rao S. Comparison of efficacy of fluconazole mouthrinse and clotrimazole mouthpaint in the treatment of oral candidiasis. Australian Dental Journal 2009;54:341-6.
45. Khozeimeh F, Shahtalebi MA, Noori M, Savabi O. Comparative evaluation of ketoconazole tablet and topical ketoconazole 2% in orabase in treatment of candida-infected denture stomatitis. J Contemp Dent Pract 2010;11:17-24.
46. Czerninski R, Pikovsky A, Gati I, Friedman M, Steinberg D. Comparison of the efficacy of a novel sustained release clotrimazole varnish and clotrimazole troches for the treatment of oral candidiasis. Clin Oral Investig 2015;19:467-73.
47. Kaminester LH, Pariser RJ, Pariser DM, Weiss JS, Shavin JS, et al. A double-blind, placebo controlled study of topical tetracaine in the treatment of herpes labialis. J Am Acad Dermatol 1999;41:996-1001.
48. Evans TG, Bernstein DI, Raborn GW, Harmenberg J, Kowalski J, et al. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocorticone cream (ME-609) for the treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother 2002;46:1870-4.
49. Hull CM, Harmenberg J, Arlander E, Aoki F, Bring J, et al. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-bind, placebo-controlled, patient-initiated cinica trial. J Am Acad Dermatol 2011;64:696.e1-11.
50. Skulason S, Holbrook WP, Thormar H, Gunnarsson GB, Krsitmundsdottir T. A study of the clinical activity of a gel combining monocaprin and doxycycline: a novel treatment for herpes labialis. J Oral Pathol Med 2012;41:61-7.
51. Senti G, Iannaccone R, Graf N, Felder M, Tay F, et al. A randomized, double-blind, placebo-controlled study to test the efficacy of topical 2-hydroxypropyl-Beta-cyclodextrin in the prophylaxis of recurrent herpes labialis. Dermatology 2013;226:247-52.
52. Merchant HW, Gangarosa LP, Glassman AB, Sobel RE. Betamethasone-17-benzoate in the treatment of recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol 1978;45:870-5.
53. Ylikontiola L, Sorsa T, Häyrinen-Immonen R, Salo T. Doxymycine-cyanoacrylate treatment of recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:329-33.
54. Darbandi A, Ganbari A. Evaluation of the effect of a clobetasol propionate and nystatin mouthwash on recurrent aphthous stomatitis. Front Dent 2006;3:117-21.
55. Liu J, Zeng X, Chen Q, Cai Y, Chen F, et al. An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:475-81.
56. Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J 2007;13:1.
57. Rodriguez M, Rubio JA, Sanchez R. Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitis. Oral Dis 2007;13:490-4.
58. Gorsky M, Epstein J, Raviv A, Yaniv R, Truelove E. Topical minocycline for managing symptoms of recurrent aphthous stomatitis. Spec Care Dentist 2008;28:27-31.
59. Meng W, Dong Y, Liu J, Wang Z, Zhong X, et al. A clinical of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial. Trials 2009;10:30.
60. Skulason S, Holbrook WP, Kristmundsdottir T. Clinical assessment of the effect of a matrix metalloproteinase inhibitor on aphthous ulcers. Acta Odontol Scand 2009;67:25-9.
61. Vijayabala GS, Kalappanavar AN, Annigeri RG, Sudarshan R, Shettar SS. Single application of topical doxycycline hyclate in the management of recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:440-6.
62. Ronal A, Permana G, Rahmayanti F. Effectiveness of clobetasol propionate 0.05% bioadhesive gel in minor recurrent aphthous stomatitis. Oral medicine [thesis]. Jakarta: Universitas Indonesia; 2014.
63. Mehdipour M, Zenooz AT, Sohrabi A, Gholizadeh N, Bahramian A, et al. A comparison of the effect of triamcinolone ointment and mouthwash with or without zinc on the healing process of aphthous stomatitis lesions. JODDD 2016;10:87-91.
64. Chandak R, Sonule S, Chandak M, Rawlani S, Gaikwad R. Efficacy of single application of topical doxycycline hyclate and triamcinolone acetonide in denture adhesive in the management of recurrent aphthous stomatitis: a comparative study. J Oral Res Rev 2017;9:72-6.
65. Mojtahedi N, Ghalayani P, Golestannejad Z, Davari A, Shahi H. Comparative evaluation of two forms of drugs: patch & lotion of clobetasol, on recovery indicators of aphthous stomatitis. Ann Dent Spec 2017;5:27-32.
66. Yarom N, Zelig K, Epstein JB, Gorsky M. The efficacy of minocycline mouth rinses on the symptoms associated with recurrent aphthous stomatitis: a randomized, double-blind, crossover study assessing different doses of oral rinses. Oral Surg Oral Med Oral Pathol Oral Radiol 2017;123:675-9.
67. Loprinzi CL, Cianflone SG, Dose AM, Etzell PS, Burnham NL, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer 1990;65:1879-82.
68. Tsavaris NB, Komitsopoulou P, Tzannou I, Loucatou P, Tsaroucha-Noutsou A, et al. Decreased oral toxicity with the local use of allopurinol in patients who received high dose 5-fluorouracil. Sel Cancer Ther 1991;7:113-7.
69. Cartee L, Petros WP, Rosner GL, Gilbert C, Moore S, et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 1995;7:471-7.
70. Malik IA, Moid I, Haq S, Sabih M. A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis. J Pain Symptom Manage 1997;14:82-7.
71. Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-5.
72. Dodd MJ, Dibble SL, Miaskowski C, MacPhil L, Greenspan D, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:39-47.
73. Hejna M, Kostler WJ, Raderer M, Steger GG, Brodowicz T, et al. Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. Euro J Cancer 2001;37:1994-2002.
74. Sprinzl GM, Galvan O, de Vries A, Ulmer H, Gunkel AR, et al. Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer 2001;37:2003-9.
75. van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann Hematol 2001;80:150-4.
76. Cerchietti LCA, Navigante AH, Bonomi MR, Zaderadjko MA, Menendez PR, et al. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 2002;95:2230-6.
77. Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. Int J Radiat Oncol Biol Phys 2002;54:479-85.
78. Valcárcel D, Sanz MA Jr, Sureda A, Sala M, Muñoz L, et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplant 2002;29:783-7.
79. Dazzi C, Cariello A, Giovanis P, Monti M, Vertogen B, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann Oncol 2003;14:559-63.
80. Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk Lymphoma 2003;44:1165-72.
81. Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 2004;28:559-65.
82. Trotti A, Garden A, Warde P, Symonds P, Langer C, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 2004;58:674-81.
83. Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Res 2004;24:1131-4.
84. Nazari M, Sadrolhefazi B, Nikoofar A, Erfan M, Azizian H, et al. Allopurinol mouthwash for prevention or alleviation radiotherapy induced oral mucositis: a randomized, placebo-controlled trial. Daru 2007;15:227-30.
85. Shabanloei R, Ahamdi F, Vaez J, Ansarin K, Hajizadeh E, et al. Allopurinol, Chamomile and normal saline mouthwashes for the prevention of chemotherapy-induced stomatitis. J Clin Diagn Res 2009;3:1537-42.
86. Baharvand M, Sarrafi M, Alavi K, Moghaddam EJ. Efficacy of topical phenytoin on chemotherapy-induced oral mucositis; a pilot study. Daru 2010;18:46-50.
87. Panahi Y, Ala S, Saeedi M, Okhovatian A, Bazzaz N, et al. Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis. European Journal of Cancer Care 2010;19:308-12.
88. Vayne-Bossert P, Escher M, Gilbert de Vautibault C, Dulguerov P, Allal A, et al. Effect of topical morphine (mouthwash) on oral pain due to chemotherapy- and/or radiotherapy-induced mucositis: a randomized double-blinded study. J Palliat Med 2010;13:125-8.
89. Watanabe T, Ishihara M, Matsuura K, Mizuta K, Itoh Y. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int J Cancer 2010;127:1984-90.
90. Mehdipour M, Zenooz AT, Kermani IA, Hosseinpour A. A comparison between zinc sulfate and chlorhexidine gluconate mouthwashes in the prevention of chemotherapy-induced oral mucositis. Daru 2011;19:71-3.
91. Yen SH, Wang LW, Lin YH, Jen YM, Chung YL. Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. Int J Radiation oncology Biol Phys 2012;82:1463-70.
92. Lambrecht M, Mercier C, Geussens Y, Nuyts S. The effect of a supersaturated calcium phosphate mouth rinse on the development of oral mucositis in head and neck cancer patients treated with (chemo)radiation. Support Care Cancer 2013;21:2663-70.
93. Leenstra JL, Miller RC, Qin R, Martenson JA, Dornfeld KJ, et al. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial. J Clin Oncol 2014;32:1571-7.
94. Hosseinjani H, Hadjibabaie M, Gholami K, Javadi M, Radfar M, et al. The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Hematol Oncol 2017;35:106-12.
95. Lin JX, Fan ZY, Lin Q, Wu Q, Wu DH, et al. A comparison of dioctahedral smectite and iodine glycerine cream with topical mouth rinse in treatment of chemotherapy induced oral mucositis: a pilot study. Eur J Oncol Nurs 2015;19:136-41.
96. Sarvizadeh M, Hemati S, Meidani M, Ashouri M, Roayaei M, et al. Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer. Adv Biomed Res 2015;4:44.
97. Ala S, Saeedi M, Janbabai G, Ganji R, Azhdari E, et al. Efficacy of sucralfate mouth wash in prevention of 5-fluorouacil induced oral mucositis: a prospective, randomized, double-blind, controlled trial. Nutr and Cancer 2016;68:456-63.
98. Park AR, La HO, Cho BS, Kim SJ, Lee BK, et al. Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease. Am J Health Syst Pharm 2013;70:1383-91.
99. Noce CW, Gomes A, Shcaira V, Corrêa ME, Moreira MC, et al. Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014;20:1163-8.
100. Treister N, Li S, Kim H, Lerman M, Sultan A, et al. An open-label phase II randomized trial of topical dexamethasone and tacrolimus solutions for the treatment of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2016;22:2084-91.
101. García-Pola MJ, González-Álvarez L, Garcia-Martin JM. Treatment of oral lichen planus. Systematic review and therapeutic guide. Med Clin (Barc) 2017;149:351-62.
102. Chamani G, Rad M, Zarei MR, Lotfi S, Sadeghi M, et al. Efficacy of tacrolimus and clobetasol in the treatment of oral lichen planus: a systematic review and meta-analysis. Int J Dermatol 2015;54:996-1004.
103. Lodi G, Carrozzo M, Furness S, Thongprasom K. Interventions for treating oral lichen planus: a systematic review. Br J Dermatol 2012;166:938-47.
104. Cheng CQ, Xu H, Liu L, Wang RN, Liu YT, et al. Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: a systematic review and meta-analysis. J Am Dent Assoc 2016;147:236-43.
105. Yang WF, Liao GQ, Hakim SG, Ouyang DQ, Ringash J, et al. Is pilocarpine effective in preventing radiation-induced xerostomia? a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2016;94:503-11.
106. Rosa MI, Souza SL, Farias BF, Pires PD, Dondossola ER, et al. Efficacy of Topical 5% Acyclovir-1% Hydrocortisone Cream (ME-609) for Treatment of Herpes Labialis: a systematic review. An Acad Bras Cienc 2015;87:1415-20.
107. Maheswari TNU, Shanmugasundaram P. Amlexanox in treatment of aphthous ulcers: A systematic review. Journal of Pharmacy Research 2013;6:214-7.
108. Piacentini M, Borghetti RL, Zancanaro de Figueiredo MA, Cherubini K, Goncalves Salum F. Doxycycline: an option in the treatment of ulcerated oral lesions? J Clin Pharm Ther 2019;44:838-43.
109. Staines K, Greenwood M. Aphthous ulcers (recurrent). Systematic review 1303. BMJ Clinical Evidence. http://clinicalevidence.bmj.com/x/systematic-review/1303/overview.html. [Last accessed on 17 Aug 2020].
110. Jensen SB, Jarvis V, Zadik Y, Barasch A, Ariyawardana A, et al. Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer 2013;21:3223-32.
111. Clarkson JE, Worthington HV, Furness S, McCabe M, Khalid T, et al. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2010:CD001973.
112. Saunders DP, Epstein JB, Elad S, Allemano J, Bossi P, et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer 2013;21:3191-207.
113. Dutta K, Garg R. Morphine mouthwash in oral mucositis: a mini review. Palliat Med Hosp Care Open J 2016;2:26-9.
